Merck to Test Promising HIV Vaccines Using NIAID Network

Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

BETHESDA, Maryland-Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

BETHESDA, Maryland—Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

The agreement will enable Merck to evaluate its vaccines in a collaborative effort with the international HIV Vaccine Trials Network (HVTN), which consists of centers at 12 US academic sites and 13 institutions in Africa, Asia, South America, and the Caribbean.

Related Videos
Experts on multiple myeloma
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Experts on multiple myeloma
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma